^
    Back
    Association details:
    Biomarker:BRAF mutation
    Cancer:Melanoma
    Drug:Stivarga (regorafenib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma

    Excerpt:
    ...Patients with BRAFV600mutant melanoma must have failed treatment with a BRAF-(+/-MEK) inhibitor....
    Trial ID:
    RegoMel
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2023
    Title:

    1136P - Regorafenib combined with BRAF-/MEK-inhibitors for the treatment of refractory melanoma brain metastases

    Published date:
    10/16/2023
    Excerpt:
    The best objective intracranial response (according to RANO-BM) in 17 response evaluable pts was: PR in 5 pts (29%; incl. 4 BRAFmt pts), and SD in 5 pts (29%; incl. 4 BRAFmt pts)….In heavily pretreated patients with refractory MBM, REGO combined with BRAF/MEKi demonstrated promising anti-tumor activity.
    Secondary therapy:
    BRAF inhibitor + MEK inhibitor